Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer

Published on Jun 1, 2021in Critical Reviews in Oncology Hematology5.833
· DOI :10.1016/J.CRITREVONC.2021.103351
Alvise Berti17
Estimated H-index: 17
(Mayo Clinic),
Roberto Bortolotti7
Estimated H-index: 7
+ 7 AuthorsAntonello Veccia14
Estimated H-index: 14
Source
Abstract
INTRODUCTION The introduction in clinical practice of the immune checkpoint inhibitors (ICIs) radically changed the treatment algorithm of lung cancers. To characterize the toxicity of ICIs (atezolizumab, durvalumab, nivolumab, pembrolizumab) is important for personalizing treatment. PATIENTS AND METHODS We performed a systematic review and meta-analysis of phase III randomized controlled trials assessing ICIs, from inception until April 23rd, 2020. We extracted the data from the ICI arm of each trial for indirect comparisons to estimate relative risk for immune-related adverse events (irAEs), severe (grade ≥3) irAEs, drug discontinuation due to irAEs or toxic death. RESULTS Sixteen trials included a total of 6226 subjects randomized to the experimental immunotherapy arm. Immunotherapy was administered in monotherapy (8 trials), in combination with chemotherapy (6 trials) or other ICI (2 trials). Any grade irAEs and severe irAEs for ICI were 37.1 % and 18.5 %, respectively. Discontinuations due to any grade irAEs and severe irAEs were 13.8 % and 9.2 %, respectively; toxic deaths were 2.9 % in the immunotherapy arm. Pooled data on any, severe and organ-specific irAEs showed that immunotherapy has a significantly lower risk of irAEs compared to immuno-chemotherapy, especially when analysis was restricted to monoimmunotherapy, like drug discontinuation and toxic death (all p < 0.05). Detailed comparisons between different ICIs provided treatment-related risk profiles for organ-specific irAEs. CONCLUSIONS Our findings contribute to clarifying frequency and features of immune-related toxicities between different ICIs in lung cancer patients, including any grade irAEs, severe irAEs, drug discontinuation and toxic deaths, and may be useful to inform the selection of treatment.
References36
Newest
#1Olga Nigro (Ospedale di Circolo e Fondazione Macchi)H-Index: 8
#2Graziella Pinotti (Ospedale di Circolo e Fondazione Macchi)H-Index: 32
Last. Alessio CortelliniH-Index: 18
view all 51 authors...
Abstract Background Data on spectrum and grade of immune-related adverse events (irAEs) in long-term responders to immune checkpoint inhibitors (ICIs) are lacking. Methods We performed a retrospective multicenter study to characterized irAEs occurring after a 12-months minimum treatment period with PD-(L)1 ICIs in patients with advanced cancer. IrAEs were categorized into ‘early’ (≤12 months) and ‘late’ (>12 months). Results From September 2013 to October 2019, 436 consecutive patients were eval...
16 CitationsSource
#1Charles Dolladille (UNICAEN: University of Caen Lower Normandy)H-Index: 8
#2Stéphane Ederhy (UPMC: Pierre-and-Marie-Curie University)H-Index: 24
Last. Joachim Alexandre (UNICAEN: University of Caen Lower Normandy)H-Index: 12
view all 14 authors...
Importance Limited information is available on the safety of a rechallenge with an immune checkpoint inhibitor (ICI) after an immune-related adverse event (irAE). Objective To identify the recurrence rate of the same irAE that prompted discontinuation of ICI therapy after an ICI rechallenge in patients with cancer and to identify the clinical features associated with such recurrences. Design, Setting, and Participants This observational, cross-sectional, pharmacovigilance cohort study examined i...
57 CitationsSource
#1Pascal Urwyler (Guy's and St Thomas' NHS Foundation Trust)H-Index: 1
#2Irina Earnshaw ('KCL': King's College London)H-Index: 1
Last. Sophie Papa ('KCL': King's College London)H-Index: 17
view all 12 authors...
Immune checkpoint inhibition has revolutionized the treatment of several solid cancers, most notably melanoma and non-small-cell lung cancer (NSCLC). Drugs targeting cytotoxic T lymphocyte antigen (CTLA)-4 and programmed cell death 1 (PD-1) have made their way into routine clinical use; however, this has not been without difficulties. Stimulation of the immune system to target cancer has been found to result in a reduction of self-tolerance, leading to the development of adverse effects that res...
16 CitationsSource
#1Naiyer A. Rizvi (CUMC: Columbia University Medical Center)H-Index: 76
#2B.C. Cho (Yonsei University)H-Index: 11
Last. Mystic InvestigatorsH-Index: 1
view all 31 authors...
Importance Checkpoint inhibitors targeting programmed cell death 1 or its ligand (PD-L1) as monotherapies or in combination with anti–cytotoxic T-lymphocyte–associated antigen 4 have shown clinical activity in patients with metastatic non–small cell lung cancer. Objective To compare durvalumab, with or without tremelimumab, with chemotherapy as a first-line treatment for patients with metastatic non–small cell lung cancer. Design, Setting, and Participants This open-label, phase 3 randomized cli...
103 CitationsSource
#1Fausto PetrelliH-Index: 45
#2Giulia GrizziH-Index: 1
Last. Matteo BrighentiH-Index: 11
view all 14 authors...
Immune-related adverse events (irAEs) are autoimmune-toxic effects associated with immune checkpoint inhibitors (ICIs) used for the treatment of advanced solid tumors. We performed a systematic review and meta-analysis of the published literature to assess the outcome for cancer patients treated wit
28 CitationsSource
#1Luis Paz-Ares (Complutense University of Madrid)H-Index: 85
#2Mikhail DvorkinH-Index: 10
Last. M. WilliamsonH-Index: 6
view all 228 authors...
Summary Background Most patients with small-cell lung cancer (SCLC) have extensive-stage disease at presentation, and prognosis remains poor. Recently, immunotherapy has demonstrated clinical activity in extensive-stage SCLC (ES-SCLC). The CASPIAN trial assessed durvalumab, with or without tremelimumab, in combination with etoposide plus either cisplatin or carboplatin (platinum–etoposide) in treatment-naive patients with ES-SCLC. Methods This randomised, open-label, phase 3 trial was done at 20...
371 CitationsSource
#1Qing-Qing Chai (SJTU: Shanghai Jiao Tong University)H-Index: 1
#2Jiangyang Du (SJTU: Shanghai Jiao Tong University)H-Index: 2
Last. Bin Wu (SJTU: Shanghai Jiao Tong University)H-Index: 12
view all 4 authors...
Background: Immune checkpoint inhibitors (ICIs) have evolved for the treatment of solid tumors. In addition to the efficacy of ICIs for cancer, the adverse events (AEs) of ICIs are also noteworthy for gradually more extensive clinical use. Objective: To conduct a systematic review and network meta-analysis to evaluate the treatment-related AEs that occurred in clinical trials using different kinds of ICIs, to explore the differences in AEs among ICIs for treating non–small cell lung cancer (NSCL...
11 CitationsSource
#1Patrick Arnaud-Coffin (HCL Technologies)H-Index: 1
#2Denis Maillet (HCL Technologies)H-Index: 16
Last. Julien PéronH-Index: 18
view all 7 authors...
The advent of immune checkpoint-inhibitors (CPI) has transformed treatment for several cancer types. This review was performed to assess the rate of adverse events (AEs) associated with the use of CPI, alone or in combinations. A review of AEs reporting quality was also performed. All publications of Randomized Clinical Trials (RCTs) assessing CPI published before December 2017 were included. To investigate the quality of AEs reporting, a set of items was defined based on the 2004 CONSORT harms ...
48 CitationsSource
#1Alessio Cortellini (University of L'Aquila)H-Index: 18
#2Rita ChiariH-Index: 29
Last. Sebastiano ButiH-Index: 24
view all 35 authors...
Abstract Background Immune-related adverse events (irAEs) developed during immunotherapy with anti-PD-1 agents, could be a predictive surrogate marker of clinical benefit in patients with advanced non–small-cell lung cancer (NSCLC). Methods Patients with NSCLC, treated with anti-PD-1 agents, were retrospectively evaluated. Univariate and multivariate analyses were performed to evaluate the relationships between types of irAEs (differentiated according to system/organ involved and to single-site/...
52 CitationsSource
#1Howard Jack WestH-Index: 15
#2Michael McCleod (Sarah Cannon Research Institute)H-Index: 17
Last. Federico Cappuzzo (AUSL: Academy for Urban School Leadership)H-Index: 78
view all 20 authors...
Summary Background Atezolizumab (a monoclonal antibody against PD-L1), which restores anticancer immunity, improved overall survival in patients with previously treated non-small-cell lung cancer and also showed clinical benefit when combined with chemotherapy as first-line treatment of non-small-cell lung cancer. IMpower130 aimed to assess the efficacy and safety of atezolizumab plus chemotherapy versus chemotherapy alone as first-line therapy for non-squamous non-small-cell lung cancer. Method...
353 CitationsSource
Cited By0
Newest